 SAN DIEGO and TORONTO, July 27, 2022 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Aptose or the Company NASDAQ: APTO, TSX: APS, a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, and Mr. Fletcher Payne, CFO of Aptose, will attend the Canaccord Genuity 42nd Annual Growth Conference, and Dr. Rice will present at the Conference: 